GlassScriptPhysician profile
Malcolm B Franklin
NPI 1043280589
$3,256.72
in general payments reported to CMS, 2019-2025
19 companies · $974 in 2025
The $974 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $201 · 2023: $1,035 · 2024: $1,047 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,056.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $574.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $524.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $387.08 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $292.72 | 2023-2025 | Spravato, Xarelto |
| Amgen INC. | $276.87 | 2023-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $235.82 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.02 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $178.54 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $175.11 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $83.65 | 2022-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $75.87 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $67.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $61.17 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.73 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $22.52 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $19.62 | 2025 | Symbravo |
| Sanofi-Aventis U.S. LLC | $18.29 | 2023 | |
| Glaxosmithkline, LLC. | $18.01 | 2023 | Arexvy, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $17.64 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malcolm Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.